Return to Listing

8 result(s) for Leukemia

PI Name Protocol # Title
Stephen Spurgeon IRB00007195 A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies
Richard Maziarz IRB00009571 A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Richard Maziarz IRB00009585 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Rachel Cook IRB00009893 S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Elie Traer IRB00010674 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed after First-Line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Michael Heinrich IRB00010886 A companion sample collection protocol to support the discovery of the mechanisms of resistance to targeted cancer therapies.
Richard Maziarz IRB00010941 A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program